Boone Capital Management LLC Raises Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Boone Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 7.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 581,843 shares of the company’s stock after acquiring an additional 38,000 shares during the period. Mirum Pharmaceuticals accounts for about 8.1% of Boone Capital Management LLC’s portfolio, making the stock its 4th largest position. Boone Capital Management LLC owned approximately 1.21% of Mirum Pharmaceuticals worth $24,059,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in Mirum Pharmaceuticals during the 4th quarter worth $10,611,000. Marshall Wace LLP raised its holdings in Mirum Pharmaceuticals by 641.6% during the 4th quarter. Marshall Wace LLP now owns 175,913 shares of the company’s stock valued at $7,274,000 after acquiring an additional 152,191 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Mirum Pharmaceuticals by 10.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock worth $58,831,000 after purchasing an additional 138,623 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Mirum Pharmaceuticals by 162.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock worth $7,317,000 after acquiring an additional 109,585 shares during the period. Finally, Loomis Sayles & Co. L P raised its position in shares of Mirum Pharmaceuticals by 15.8% in the fourth quarter. Loomis Sayles & Co. L P now owns 578,024 shares of the company’s stock worth $23,901,000 after buying an additional 78,708 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $44.15 on Tuesday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market cap of $2.18 billion, a PE ratio of -21.86 and a beta of 0.95. The firm’s 50-day simple moving average is $43.10 and its two-hundred day simple moving average is $44.19. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.83 and a fifty-two week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, Director Patrick J. Heron acquired 1,335 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average cost of $45.57 per share, for a total transaction of $60,835.95. Following the purchase, the director now owns 163,643 shares in the company, valued at $7,457,211.51. The trade was a 0.82 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the transaction, the senior vice president now owns 4,841 shares in the company, valued at approximately $214,698.35. This trade represents a 92.25 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 92,764 shares of company stock valued at $4,109,161. 22.87% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $58.20.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.